Release this Report to Investors

Via Email

Via Text


If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us

We are excited to present Bayer A.G. (OTC: BAYRY).

Full DD Report for BAYRY

Recent News from (OTC: BAYRY)

Monsanto -5% as Bayer tie-up reportedly faces more antitrust hurdles
Monsanto ( MON -4.6% ) shares drop sharply following a Bloomberg report that its pending takeover by Bayer ( OTCPK:BAYRY +0.1% ) faces additional hurdles for U.S. antitrust approval . More news on: Monsanto Company, Bayer A.G. ADR, Commodities news, Merger & acquisition news, Stoc...
Source: SeekingAlpha
Date: March, 15 2018 11:59
Reuters: Bayer sees progress in talks with Russia over Monsanto deal
Bayer ( OTCPK:BAYRY +0.4% ) says progress is being made in talks with Russia’s competition watchdog FAS over the company’s planned takeover of Monsanto ( MON -0.5% ). More news on: Bayer A.G. ADR, Monsanto Company, Commodities news, Merger & acquisition news, Re...
Source: SeekingAlpha
Date: March, 14 2018 14:41
China conditionally approves Bayer takeover of Monsanto
China's Commerce Ministry approves Bayer's ( OTCPK:BAYRY ) planned purchase of Monsanto (NYSE: MON ) but on condition of spinning off more assets. More news on: Bayer A.G. ADR, Monsanto Company, Commodities news, Merger & acquisition news, Read more ...
Source: SeekingAlpha
Date: March, 13 2018 07:43
3 Things In Biotech, March 10: Merck In MS, Bayer's Essure Scrutinized, Tocagen An Orphan
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec...
Source: SeekingAlpha
Date: March, 11 2018 09:34
Judge's Order Sets 1,200 Xarelto Product Liability Lawsuits for Separate Jury Trials
NEW ORLEANS , March 8, 2018 /PRNewswire/ -- A federal district judge in New Orleans has ordered that 1,200 product defect lawsuits against leading prescription painkiller Xarelto be prepared for trial in federal courts across the country. The decision by U.S. District Judge Eldo...
Source: PR Newswire
Date: March, 08 2018 16:33
Bayer says in exclusive talks to sell vegetable seeds business to BASF
Bayer ( OTCPK:BAYRY ) and BASF ( OTCQX:BASFY ) say they have entered exclusive talks on the sale of Bayer's Nunhems vegetable seeds business to address antitrust regulators’ concern over their planned merger with Monsanto (NYSE: MON ). More news on: Bayer A.G. ADR, BASF SE AD...
Source: SeekingAlpha
Date: March, 07 2018 07:55
Reuters: BASF looking to buy Bayer's vegetable seed business
BASF ( OTCQX:BASFY ) is in advanced talks to buy Bayer's ( OTCPK:BAYRY ) vegetable seeds business, which is valued at ~€1.5B ($1.85B) including debt, Reuters reports. More news on: BASF SE ADR, Bayer A.G. ADR, Monsanto Company, Commodities news, Merger & acquisition news, ...
Source: SeekingAlpha
Date: March, 02 2018 16:02
Reuters: Bayer-Monsanto merger set to be approved by EU
Bayer ( OTCPK:BAYRY ) is poised to win approval from the European Union for its proposed $63B takeover of Monsanto (NYSE: MON ), according to a Reuters report. More news on: Bayer A.G. ADR, Monsanto Company, Commodities news, Merger & acquisition news, Read more ...
Source: SeekingAlpha
Date: February, 28 2018 07:57
CNBC: EU eyes Bayer-Monsanto merger outcome before mid-year
The European Union will announce during H1 of this year whether it approves Bayer's ( OTCPK:BAYRY ) planned takeover of Monsanto (NYSE: MON ), EU Competition Commissioner Margrethe Vestager tells CNBC. More news on: Bayer A.G. ADR, Monsanto Company, Merger & acquisition news, Rea...
Source: SeekingAlpha
Date: February, 27 2018 07:46
Regeneron's Eylea sees uptick in side effects, cause unknown
For reasons undetermined, there has been an increase in unwanted side effects after the administration of Regeneron's ( REGN ) EYLEA (aflibercept). In 2017, the FDA received 71 reports of patients experiencing a sharp decline in sight and pain after receiving an intravitreal injection of t...
Source: SeekingAlpha
Date: February, 22 2018 14:07


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report.

About Bayer A.G. (OTC: BAYRY)

Logo for Bayer A.G. (OTC: BAYRY)

Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high tech materials. At the same time Bayer creates value through innovation, growth and improved earning power. lt br / gt lt br / gt Bayer HealthCare AG researches, develops, manufactures and markets innovative products for disease prevention, diagnosis and treatment. Bayer CropScience AG is a global leader in crop protection and non agricultural pest control. Bayer MaterialScience AG is a renowned supplier of high performance materials and innovative system solutions used in a wide range of products for everyday life. lt br / gt lt br / gt The Group is committed to the principles of sustainable development and acknowledges and accepts its role as a socially and ethically responsible corporate citizen, Economy, ecology and social responsibility are corporate policy objectives of equal rank. In fiscal , More information is available on the Internet at


Contact Information



Current Management

  • Dr. Marijn Dekkers / CEO
  • Werner Wenning / CFO
  • Martin Eisenhauer / Securities Counsel
  • Peter Dahlhoff / IR

Current Share Structure


    Daily Technical Chart for (OTC: BAYRY)

    Daily Technical Chart for (OTC: BAYRY)

    Stay tuned for daily updates and more on (OTC: BAYRY)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: BAYRY)

    Do your DD and if you choose, be ready to go!


    The Research: All source information contained in this email is from the public sources mentioned below.



    Thank you

    Monsta Trader



    Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BAYRY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $0 from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of BAYRY and does not buy, sell, or trade any shares of BAYRY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by Monsta Trader. All rights reserved. Our Full Disclaimer: